Antibiotic development increased, but still insufficient While the pipeline of new antibiotics has improved over the past six years, momentum in the development of new infection-fighting agents remains inadequate and could take a significant downturn without new incentives, a report released in Clinical Infectious Diseases shows. This report, an update of progress…..
Digital fusion: how smart collaborations will drive the healthcare revolution Convergence of digital technology and healthcare – digital health – has become a key driver of change for healthcare systems globally, with the mass adoption of digital technologies set to revolutionise healthcare and patient wellbeing. Payors and healthcare and life…..
Imabiotech, a French CRO based in Lille (France) and in Boston (USA), is expanding its range of services. This company is offering innovative imaging services and software to the pharmaceutical research sector. These services are based on histology combined to label free molecular imaging (Quantitative Mass Spectrometry Imaging, QMSI) . This technology…..
FEATURE STORY ● AllergoOncology: microbiota in allergy and cancer - an EAACI position paper BASIC SCIENCE ● The 1000IBD project: multi-omics data of 1000 inflammatory bowel disease patients ● Effect of the nursing mother on the gut microbiome of the offspring during early mouse development ● Enhancement of the gut barrier integrity by…..
An inhalable form of mRNA for the treatment of lung diseases About 80 RNA therapeutics are currently in clinical trial. Among these drug candidates, mRNA, which can induce cells to produce therapeutic proteins, holds great promise for treating a variety of diseases. The biggest obstacle to this approach so far…..
RNA science is now translated into new therapies… Last August, the FDA approved the first RNAi therapy, Onpattro®… RNA drugs allow precised silencing or activation of genes… RNA drugs can address a wide range of common and rare diseases… More than 60 rare or common diseases are currently targeted…. BioPharmAnalyses…..
The European Medicine Agency (EMA) is launching a six-month public consultation on its draft ‘ Regulatory Science to 2025’ strategy for a six-month public consultation. This sixty-page document proposes the plan for advancing the Agency’s engagement with regulatory science over the next five to ten years, covering both human and veterinary medicines. The…..
Sepsis is an overreaction of the body's immune system to an infection. Cytokines flood the bloodstream in an attempt to fight the infection but also cause blood vessels to become leaky. White blood cells escape from the vessels, causing inflammation and damage to surrounding tissue, ultimately leading to multi-organ failure…..
Cancer develops as a result of the accumulation of mutations in cells. These mutations are not distributed evenly in chromosomes, so some regions hold more than others. A study headed by Institute for Research in Biomedicine (IRB Barcelona) researchers Salvador Aznar Benitah and Fran Supek examined whether the opening of…..